Valuation: Tenax Therapeutics, Inc.

Market Cap 795M 693M 640M 587M 1.12B 76.51B 1.13B 7.62B 2.99B 37.37B 2.99B 2.92B 129B P/E 2026 *
-10.9x
P/E 2027 * -11.2x
Enterprise Value 795M 693M 640M 587M 1.12B 76.51B 1.13B 7.62B 2.99B 37.37B 2.99B 2.92B 129B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.88%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day-1.41%
1 week-11.74%
Current month+5.43%
1 month+33.62%
3 months+3.79%
6 months-16.04%
Current year+25.84%
1 week 15.03
Extreme 15.03
19.4
1 month 11.2
Extreme 11.2
19.4
Current year 10.25
Extreme 10.25
19.4
1 year 5.77
Extreme 5.7719
19.4
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,135.04
10 years 2.77
Extreme 2.77
86,400
Manager TitleAgeSince
Chief Executive Officer 52 13/07/2021
Director of Finance/CFO 58 10/05/2026
Chief Tech/Sci/R&D Officer - 20/01/2025
Director TitleAgeSince
Chairman 67 31/05/2021
Director/Board Member 76 24/02/2021
Director/Board Member 69 24/02/2021
Date Insider Type Main position Quantity % Market Cap.
05-10Free

Chief Financial Officer

460,000 2.6748%
05-10Other

Chief Financial Officer

0 0%
01-29Other

Controller/Auditor

50,000 0.8008%
Change 5-day change 1-year change 3-year change Capi.($)
-1.41%-11.74%+160.00%-37.54% 795M
-0.17%+1.22%+2.98%+6.80% 50.35B
-0.29%-3.16%+380.69%+591.82% 39.32B
-0.49%-0.68%+29.15%-6.46% 34.69B
+1.53%+0.74%+23.45%+58.54% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
+1.13%+0.60% - - 16.49B
-1.29%-3.12%+65.20%+117.60% 15.31B
+0.43%+0.55%+15.19%+17.46% 13.8B
+2.45%+1.99%+15.09%-30.12% 12.87B
Average +0.36%-1.41%+77.33%+82.83% 24.43B
Weighted average by Cap. +0.39%-0.35%+81.51%+121.74%

Financials

2026 *2027 *
Net sales - -
Net income -82.43M -71.9M -66.33M -60.88M -116M -7.93B -118M -790M -310M -3.88B -309M -303M -13.36B -97.73M -85.25M -78.65M -72.18M -137M -9.41B -140M -937M -368M -4.59B -367M -359M -15.84B
Net Debt - -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
15/07/26 US$15.34 -1.41% 967,420
14/07/26 US$15.56 -2.63% 1,272,470
13/07/26 US$15.98 -8.95% 1,299,236
10/07/26 US$17.55 -4.20% 1,049,686
09/07/26 US$18.32 +3.33% 1,532,320
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.56USD
Average target price
34.88USD
Spread / Average Target
+124.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock